Ipamorelin research, logged study by study.

The gist

Ipamorelin research splits cleanly into two stacks. The animal and lab studies are detailed and mostly positive — they measured a clean GH pulse, dose-dependent bone growth in rats, and protection against weight loss in ferrets. The human studies are two: how the body clears the peptide, and one trial of whether it helps bowel recovery. The trial failed.

The mechanism in plain terms: ipamorelin docks on the ghrelin receptor (GHS-R1a) on pituitary cells and triggers a short burst of growth hormone. Unlike older peptides in its class, it does this without raising cortisol or prolactin — a property called selectivity ^[1]. Below, each major finding gets its own block, with the dose, the species, and the source. Where the data is precise, the numbers are precise. Where it is missing — long-term human safety, most outcome claims — that is stated, not filled.

Mechanism: a selective GH pulse

Ipamorelin activates GHS-R1a — the ghrelin receptor — on pituitary somatotrophs (the GH-making cells). Receptor binding runs through Gq/PLC signaling, raising intracellular calcium, which releases growth hormone. It works by a route distinct from GHRH (growth-hormone-releasing hormone), which is the basis for combining it with GHRH analogs ^[1].

The defining 1998 study measured potent GH release in primary rat pituitary cells, anaesthetized rats, and conscious swine. Swine GH ED50 was 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6. The selectivity held at more than 200-fold above the GH ED50: no rise in ACTH or cortisol beyond the GHRH baseline ^[1]. That characterization was acute, not chronic — a point worth keeping when chronic-use claims appear elsewhere.

Human pharmacokinetics

Population PK/PD modeling in healthy male volunteers (n=8 per dose level) used five 15-minute IV infusions spanning 4.21 to 140.45 nmol/kg. Kinetics were dose-proportional. Terminal half-life was about 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. The GH response was a single discrete pulse peaking near 0.67 h — roughly 40 minutes — after dosing ^[2].

This is one of the only human ipamorelin datasets in existence. The dedicated read on clearance and detection windows is on the how long does ipamorelin stay in your system page.

The one human trial — and its result

The single published Phase 2 RCT (NCT00672074) enrolled 114 adults undergoing bowel resection, dosed at 0.03 mg/kg IV twice daily for up to seven days ^[3]. Median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo — not statistically significant (p=0.15). The primary endpoint was not met ^[3].

Adverse events were comparable to placebo over that window: 87.5% versus 94.8% ^[3]. The trial is the defining human efficacy and safety anchor for ipamorelin, and efficacy was not demonstrated.

Bone growth and body composition in rodents

Subcutaneous ipamorelin at 18, 90, and 450 microg/day (divided three times daily, 15 days) raised longitudinal bone-growth rate in adult female Sprague-Dawley rats from 42 microm/day on vehicle to 44, 50, and 52 microm/day — dose-dependent — with no measured change in total IGF-1, IGFBPs, or bone-turnover markers ^[4]. The lack of systemic IGF-1 change points to a partly local, GH-pulse-driven skeletal effect.

Separately, an oral ipamorelin-derived analog (NN703) produced significant body-weight gain over 14 days in rats, confirming that GH-secretagogue activity in this series shifts body composition through sustained GH-axis activation ^[7]. NN703 also showed a 4.1-hour half-life and 30% oral bioavailability in dogs, but a 50% cortisol increase at all doses — a less selective profile than ipamorelin itself ^[7].

The most recent in-vivo data (2024)

The freshest ipamorelin study is a 2024 ferret experiment. Intraperitoneal ipamorelin at 1-3 mg/kg inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48-72 h), but had no anti-emetic effect on either acute or delayed emesis ^[5]. By contrast, intracerebroventricular anamorelin reduced acute emesis by 60% in the same model ^[5].

The takeaway: ipamorelin protected against chemotherapy-associated weight loss through a peripheral mechanism, without touching nausea. It is the most recent, and among the most defensible, in-vivo ipamorelin findings.

Altered response in metabolic disease

Pharmacodynamics shift in a diabetic state. In streptozotocin-diabetic mice, IV ipamorelin produced markedly greater GH hypersecretion (150 +/- 35 µg/L) than in non-diabetic controls (62 +/- 11 µg/L), alongside hepatic GH-receptor resistance and suppressed IGF-1 ^[8]. The pattern — high GH, blunted IGF-1 — mirrors the catabolic GH-axis disruption seen in human type 1 diabetes, and is part of why glucose dysregulation is a flagged caution on Ipamorelin effects.

What is ipamorelin peptide

Ipamorelin peptide is a wholly synthetic pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C38H49N9O5, molecular weight about 711.85 Da, CAS 170851-70-4. The alpha-aminoisobutyric acid at position 1 and the D-form amino acids confer resistance to enzymatic breakdown. It was derived from GHRP-1 by removing the central Ala-Trp dipeptide ^[1]. Functionally, it is a selective ghrelin-receptor (GHS-R1a) agonist that releases growth hormone — and it is not an endogenous human peptide; it mimics ghrelin's action at the receptor.

What is cjc 1295 ipamorelin

What is cjc 1295 ipamorelin: it is a two-peptide pairing, not a single drug. CJC-1295 is a GHRH analog (it acts on the GHRH receptor); ipamorelin is a GHS-R1a agonist (it acts on the ghrelin receptor). The two arms of GH control are mechanistically distinct, which is the rationale for combining them. Their GH-releasing effects can be synergistic — in rats neutralized of endogenous GHRH and somatostatin, combined GHRH plus a GHRP produced GH peaks significantly greater than the sum of the individual peaks ^[9].

Ipamorelin cjc-1295

The ipamorelin cjc-1295 synergy has a documented mechanistic basis. Endogenous GHRH is required for full GHRP activity: GHRP-6 activity in rats was significantly attenuated by GHRH antiserum or GHRH-receptor blockade ^[10], and in GHRH-knockout mice, GHRP-2 alone failed to stimulate GH while GHRP-2 plus a GHRH analog produced superior growth outcomes ^[11]. In ovine pituitary cells, GHRH plus GHRP-2 upregulated GH mRNA, GHS-R, GHRH-R, and Pit-1 expression in a time-dependent manner ^[12]. These are class-level studies — they use GHRP-6 and GHRP-2, not ipamorelin — and they explain why a GHRH analog is stacked with a ghrelin-receptor agonist. No trial of the cjc-1295 ipamorelin combination for any clinical outcome exists.

Does cjc-1295 ipamorelin work

Does cjc-1295 ipamorelin work: for raising GH in animal models, the underlying pharmacology is real — GHRH-analog plus GHRP synergy exceeds additive GH release in controlled rat experiments ^[9]. For human outcomes — body composition, recovery, anti-aging — there is no controlled trial of the combination, and the single human ipamorelin trial that did run, for bowel recovery, failed ^[3]. The mechanism is established; the human outcome claims are not.

Ipamorelin vs sermorelin

Ipamorelin vs sermorelin is a comparison across two different receptor systems. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist — a growth-hormone-releasing peptide. Sermorelin is a GHRH analog: it mimics growth-hormone-releasing hormone and acts on the GHRH receptor. They sit on opposite arms of GH control, which is exactly why GHRP-class and GHRH-class compounds are studied in combination rather than as substitutes ^[9]. Ipamorelin's selling trait is selectivity — GH release without cortisol or prolactin elevation ^[1]; that selectivity is a property of the ghrelin-receptor arm, not the GHRH arm.

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin contrasts an unapproved research peptide with an approved drug on a different mechanism. Tesamorelin is a stabilized GHRH analog (GHRH-receptor agonist). Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist ^[1]. The mechanisms differ in the same way as the sermorelin comparison — GHRH arm versus GHRP arm. The sharper contrast is regulatory: ipamorelin has never been approved for any indication and its one Phase 2 trial failed ^[3]. Tesamorelin carries an approved indication of its own. This site does not extend tesamorelin's clinical data to ipamorelin; the two are not interchangeable.